The impact of COVID-19 on clinical course and treatment among patients with juvenile systemic sclerosis.

IF 1.1 4区医学 Q4 Medicine

Archives of rheumatology Pub Date : 2023-06-01 DOI:10.46497/ArchRheumatol.2023.9636

Amra Adrovic, Mehmet Yıldız, Fatih Haşlak, Sezgin Şahin, Oya Köker, Aybüke Günalp, Kenan Barut, Özgür Kasapçopur

{"title":"The impact of COVID-19 on clinical course and treatment among patients with juvenile systemic sclerosis.","authors":"Amra Adrovic, Mehmet Yıldız, Fatih Haşlak, Sezgin Şahin, Oya Köker, Aybüke Günalp, Kenan Barut, Özgür Kasapçopur","doi":"10.46497/ArchRheumatol.2023.9636","DOIUrl":null,"url":null,"abstract":"Objectives: This study aimed to explore the influence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic among patients with juvenile systemic sclerosis (JSS).Patients and methods: Twenty-seven patients (22 females, 5 males; mean age: 20 years; range, 17 to 22 years) diagnosed with JSS and followed up at the department of pediatric rheumatology were included in the cross-sectional study. A web-based survey was performed by focusing on patients' complaints, accessibility to health care, and compliance with routine treatment from January 1, 2021, to January 10, 2021.Results: Five (18.5%) patients had deterioration of the disease, while six (22.2%) patients reported irregular usage of their routine scleroderma treatment during the last six months. Nine (33.3%) patients had missed their routine clinic control since the proclamation of the SARS-CoV-2 pandemic. Seven (25.9%) patients had household contact with coronavirus disease 2019 (COVID-19). Four (14.8%) patients were diagnosed with COVID-19, and only one (3.7%) was hospitalized. Nine patients were under biological treatment (tocilizumab); however, only one of them was diagnosed with COVID-19.Conclusion: The COVID-19 pandemic has not significantly disrupted the medical care of JSS patients. Telemedicine could be an acceptable option for JSS patients disenabled to come to the hospital.","PeriodicalId":8328,"journal":{"name":"Archives of rheumatology","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/82/b2/ArchRheumatol-2023-38-267.PMC10481691.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.46497/ArchRheumatol.2023.9636","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: This study aimed to explore the influence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic among patients with juvenile systemic sclerosis (JSS).

Patients and methods: Twenty-seven patients (22 females, 5 males; mean age: 20 years; range, 17 to 22 years) diagnosed with JSS and followed up at the department of pediatric rheumatology were included in the cross-sectional study. A web-based survey was performed by focusing on patients' complaints, accessibility to health care, and compliance with routine treatment from January 1, 2021, to January 10, 2021.

Results: Five (18.5%) patients had deterioration of the disease, while six (22.2%) patients reported irregular usage of their routine scleroderma treatment during the last six months. Nine (33.3%) patients had missed their routine clinic control since the proclamation of the SARS-CoV-2 pandemic. Seven (25.9%) patients had household contact with coronavirus disease 2019 (COVID-19). Four (14.8%) patients were diagnosed with COVID-19, and only one (3.7%) was hospitalized. Nine patients were under biological treatment (tocilizumab); however, only one of them was diagnosed with COVID-19.

Conclusion: The COVID-19 pandemic has not significantly disrupted the medical care of JSS patients. Telemedicine could be an acceptable option for JSS patients disenabled to come to the hospital.

Abstract Image

查看原文本刊更多论文

COVID-19对青少年系统性硬化症患者临床病程及治疗的影响

目的:探讨严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)大流行对青少年系统性硬化症(JSS)患者的影响。患者与方法:27例患者，其中女性22例，男性5例;平均年龄:20岁;被诊断为JSS并在儿科风湿病科随访的患者(年龄在17至22岁之间)被纳入横断面研究。在2021年1月1日至2021年1月10日期间，开展了一项基于网络的调查，重点关注患者的投诉、获得医疗保健的机会以及对常规治疗的依从性。结果:5例(18.5%)患者病情恶化，6例(22.2%)患者报告在过去6个月内不规律地使用常规硬皮病治疗。自SARS-CoV-2大流行宣布以来，有9例(33.3%)患者未进行常规临床控制。7例(25.9%)患者有家庭接触史。4例(14.8%)患者被诊断为COVID-19，只有1例(3.7%)患者住院。9例患者接受生物治疗(托珠单抗);然而，其中只有一人被诊断出患有COVID-19。结论:新冠肺炎疫情对JSS患者的医疗护理影响不明显。远程医疗对于无法来医院的JSS患者来说是一个可接受的选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Archives of rheumatology Medicine-Rheumatology

CiteScore

2.00

自引率

9.10%

发文量

期刊介绍： The Archives of Rheumatology is an official journal of the Turkish League Against Rheumatism (TLAR) and is published quarterly in March, June, September, and December. It publishes original work on all aspects of rheumatology and disorders of the musculoskeletal system. The priority of the Archives of Rheumatology is to publish high-quality original research articles, especially in inflammatory rheumatic disorders. In addition to research articles, brief reports, reviews, editorials, letters to the editor can also be published. It is an independent peer-reviewed international journal printed in English. Manuscripts are refereed by a "double-blind peer-reviewed" process for both referees and authors. Editorial Board of the Archives of Rheumatology works under the principles of The World Association of Medical Editors (WAME), the International Council of Medical Journal Editors (ICMJE), and Committee on Publication Ethics (COPE).